MX2021003628A - Metodos para reducir la agregacion de anticuerpos biespecificos. - Google Patents
Metodos para reducir la agregacion de anticuerpos biespecificos.Info
- Publication number
- MX2021003628A MX2021003628A MX2021003628A MX2021003628A MX2021003628A MX 2021003628 A MX2021003628 A MX 2021003628A MX 2021003628 A MX2021003628 A MX 2021003628A MX 2021003628 A MX2021003628 A MX 2021003628A MX 2021003628 A MX2021003628 A MX 2021003628A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- reducing aggregation
- bispecific antibodies
- bispecific
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención descrita en el presente documento se refiere a métodos para reducir la agregación de anticuerpos biespecíficos, por ejemplo, reducir la agregación de construcciones de anticuerpos acopladores de linfocitos T biespecíficos (BiTE), debida al almacenamiento en condiciones de congelación mediante la retención de los anticuerpos a determinadas temperaturas después de la descongelación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862739542P | 2018-10-01 | 2018-10-01 | |
PCT/US2019/053462 WO2020072306A1 (en) | 2018-10-01 | 2019-09-27 | Methods for reducing aggregation of bispecific antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021003628A true MX2021003628A (es) | 2021-05-27 |
Family
ID=70055398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021003628A MX2021003628A (es) | 2018-10-01 | 2019-09-27 | Metodos para reducir la agregacion de anticuerpos biespecificos. |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP3860567A4 (es) |
JP (1) | JP2022512569A (es) |
KR (1) | KR20210070314A (es) |
CN (1) | CN112789028A (es) |
AU (1) | AU2019351715A1 (es) |
BR (1) | BR112021006220A2 (es) |
CA (1) | CA3112655A1 (es) |
CL (1) | CL2021000827A1 (es) |
EA (1) | EA202190955A1 (es) |
IL (1) | IL281621A (es) |
MA (1) | MA53831A (es) |
MX (1) | MX2021003628A (es) |
SG (1) | SG11202102995PA (es) |
WO (1) | WO2020072306A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022046651A1 (en) * | 2020-08-24 | 2022-03-03 | Amgen Inc. | Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine |
AU2021345124A1 (en) * | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
WO2022060878A1 (en) * | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for treating prostate cancer |
IL308847A (en) * | 2021-06-30 | 2024-01-01 | Amgen Inc | The method of recovering a freeze-dried formulation |
WO2024059675A2 (en) * | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102106002B1 (ko) * | 2011-10-11 | 2020-05-07 | 제넨테크, 인크. | 이중특이적 항체의 개선된 어셈블리 |
PT2916866T (pt) * | 2012-11-06 | 2018-07-10 | Amgen Inc | Formulação para ativadores de células t bispecíficas (bites) |
TWI679019B (zh) * | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗il-4/抗il-13之雙特異性抗體調配物 |
JP6769879B2 (ja) * | 2014-05-07 | 2020-10-14 | タケダ・ゲー・エム・ベー・ハーTakeda GmbH | Gm−csf中和化合物を含む液体製剤 |
WO2016036678A1 (en) * | 2014-09-02 | 2016-03-10 | Medimmune, Llc | Formulations of bispecific antibodies |
WO2017121867A1 (en) * | 2016-01-13 | 2017-07-20 | Genmab A/S | Formulation for antibody and drug conjugate thereof |
TWI797073B (zh) * | 2016-01-25 | 2023-04-01 | 德商安美基研究(慕尼黑)公司 | 包含雙特異性抗體建構物之醫藥組合物 |
SI3411404T1 (sl) * | 2016-02-03 | 2023-01-31 | Amgen Research (Munich) Gmbh | Konstrukti bispecifičnih protiteles PSMA in CD3, ki aktivirajo T celico |
AR111773A1 (es) * | 2017-05-05 | 2019-08-21 | Amgen Inc | Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración |
EA202091422A1 (ru) * | 2017-12-11 | 2020-08-28 | Эмджен Инк. | Способ непрерывного производства продуктов на основе биспецифических антител |
-
2019
- 2019-09-27 SG SG11202102995PA patent/SG11202102995PA/en unknown
- 2019-09-27 EP EP19869416.8A patent/EP3860567A4/en active Pending
- 2019-09-27 CA CA3112655A patent/CA3112655A1/en active Pending
- 2019-09-27 KR KR1020217012083A patent/KR20210070314A/ko unknown
- 2019-09-27 AU AU2019351715A patent/AU2019351715A1/en active Pending
- 2019-09-27 CN CN201980064486.6A patent/CN112789028A/zh active Pending
- 2019-09-27 WO PCT/US2019/053462 patent/WO2020072306A1/en unknown
- 2019-09-27 EA EA202190955A patent/EA202190955A1/ru unknown
- 2019-09-27 MX MX2021003628A patent/MX2021003628A/es unknown
- 2019-09-27 MA MA053831A patent/MA53831A/fr unknown
- 2019-09-27 BR BR112021006220A patent/BR112021006220A2/pt unknown
- 2019-09-27 JP JP2021517615A patent/JP2022512569A/ja active Pending
-
2021
- 2021-03-18 IL IL281621A patent/IL281621A/en unknown
- 2021-04-01 CL CL2021000827A patent/CL2021000827A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL281621A (en) | 2021-05-31 |
BR112021006220A2 (pt) | 2021-07-06 |
EP3860567A1 (en) | 2021-08-11 |
CA3112655A1 (en) | 2020-04-09 |
KR20210070314A (ko) | 2021-06-14 |
EP3860567A4 (en) | 2022-07-06 |
CN112789028A (zh) | 2021-05-11 |
AU2019351715A1 (en) | 2021-04-22 |
MA53831A (fr) | 2022-01-05 |
JP2022512569A (ja) | 2022-02-07 |
SG11202102995PA (en) | 2021-04-29 |
CL2021000827A1 (es) | 2021-10-15 |
WO2020072306A1 (en) | 2020-04-09 |
EA202190955A1 (ru) | 2021-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021003628A (es) | Metodos para reducir la agregacion de anticuerpos biespecificos. | |
AR096839A1 (es) | Proceso mejorado para la producción de anticuerpos monoclonales | |
AU2018366199A1 (en) | Bispecific and monospecific antibodies using novel anti-PD-1 sequences | |
MX2022000132A (es) | Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t. | |
MX2021009926A (es) | Agonistas il-2rbeta-selectivos en combinacion con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1. | |
AR113342A1 (es) | Anticuerpos específicos cd47 / pd-l1 | |
CL2017003195A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso. | |
EP4257613A3 (en) | Bispecific checkpoint inhibitor antibodies | |
CO2017006808A2 (es) | Receptores de antígenos quiméricos de bcma | |
BR112018067698A2 (pt) | células modificadas para imunoterapia | |
CL2017001866A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
MX2022002364A (es) | Anticuerpos anti-pd-l1. | |
SG10201900571YA (en) | Anti-pd-1 antibodies | |
WO2019008123A3 (en) | CELLS, VERTEBRATES, POPULATIONS AND METHODS | |
MX2020001450A (es) | Composiciones para reducir la inmunosupresion por celulas de tumor. | |
NZ735778A (en) | Kappa myeloma antigen chimeric antigen receptors and uses thereof | |
IL276975A (en) | Chimeric antigen receptor cell immunotherapy with a bispecific antibody | |
MX2021003169A (es) | Metodos para purificar anticuerpos multiespecificos, heterodimericos. | |
MX2020012589A (es) | Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos. | |
PH12019502575A1 (en) | Btla agonist antibodies and uses thereof | |
MX2019011585A (es) | Anticuerpos miltiespecificos estables. | |
EA201792661A1 (ru) | Способ получения антител против т-клеточного рецептора | |
MX2023004275A (es) | Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos. | |
BR112021011529A2 (pt) | Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado | |
MX2021000797A (es) | Anticuerpos agonistas de cd226. |